Publications (Pre-2010)

118. Mottet, D., Pirotte, S., Lamour, V., Hagedorn, M., Javerzat, S., Bikfalvi, A., Bellahcene, A., Verdin, E., and Castronovo, V., HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene, 2009. 28(2): p. 243-56. 

117. Hirschey, M.D., Shimazu, T., Huang, J.Y., and Verdin, E., Acetylation of mitochondrial proteins. Methods Enzymol, 2009. 457: p. 137-47.

116. Schafer, S., Saunders, L., Schlimme, S., Valkov, V., Wagner, J.M., Kratz, F., Sippl, W., Verdin, E., and Jung, M., Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. ChemMedChem, 2009. 4(2): p. 283-90.

115. Kauder, S.E., Bosque, A., Lindqvist, A., Planelles, V., and Verdin, E., Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog, 2009. 5(6): p. e1000495.

114. Saunders, L.R. and Verdin, E., Cell biology. Stress response and aging. Science, 2009. 323(5917): p. 1021-2.

113. Cooper, H.M., Huang, J.Y., Verdin, E., and Spelbrink, J.N., A new splice variant of the mouse SIRT3 gene encodes the mitochondrial precursor protein. PLoS One, 2009. 4(3): p. e4986.

112. Blazkova, J., Trejbalova, K., Gondois-Rey, F., Halfon, P., Philibert, P., Guiguen, A., Verdin, E., Olive, D., Van Lint, C., Hejnar, J., and Hirsch, I., CpG methylation controls reactivation of HIV from latency. PLoS Pathog, 2009. 5(8): p. e100055.

111. Pintchovski, S.A., Peebles, C.L., Kim, H.J., Verdin, E., and Finkbeiner, S., The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons. J Neurosci, 2009. 29(5): p. 1525-37.

110. Verdin, E., Regulation of human immunodeficiency virus-1 latency and its reactivation. Bull Mem Acad R Med Belg, 2008. 163(6): p. 355-64; discussion 364-5.

109. Neugebauer, R.C., Uchiechowska, U., Meier, R., Hruby, H., Valkov, V., Verdin, E., Sippl, W., and Jung, M., Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J Med Chem, 2008. 51(5): p. 1203-13.

108. Uciechowska, U., Schemies, J., Neugebauer, R.C., Huda, E.M., Schmitt, M.L., Meier, R., Verdin, E., Jung, M., and Sippl, W., Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing. ChemMedChem, 2008. 3(12): p. 1965-76.

107. Wang, S., Li, X., Parra, M., Verdin, E., Bassel-Duby, R., and Olson, E.N., Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A, 2008. 105(22): p. 7738-43.

106. Schafer, S., Saunders, L., Eliseeva, E., Velena, A., Jung, M., Schwienhorst, A., Strasser, A., Dickmanns, A., Ficner, R., Schlimme, S., Sippl, W., Verdin, E., and Jung, M., Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg Med Chem, 2008. 16(4): p. 2011-33.

105. Schwer, B. and Verdin, E., Conserved metabolic regulatory functions of sirtuins. Cell Metab, 2008. 7(2): p. 104-12.

104. Scott, G.K., Marx, C., Berger, C.E., Saunders, L.R., Verdin, E., Schafer, S., Jung, M., and Benz, C.C., Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res, 2008. 6(7): p. 1250-8.

103. Kasler, H.G. and Verdin, E., Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol Cell Biol, 2007. 27(14): p. 5184-200.

102. Bisgrove, D.A., Mahmoudi, T., Henklein, P., and Verdin, E., Conserved P-TEFb- interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci U S A, 2007. 104(34): p. 13690-5.

101. Krennhrubec, K., Marshall, B.L., Hedglin, M., Verdin, E., and Ulrich, S.M., Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett, 2007. 17(10): p. 2874-8.

100. Barrett, A., Santangelo, S., Tan, K., Catchpole, S., Roberts, K., Spencer-Dene, B., Hall, D., Scibetta, A., Burchell, J., Verdin, E., Freemont, P., and Taylor-Papadimitriou, J., Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int J Cancer, 2007. 121(2): p. 265-75.

99. Lombard, D.B., Alt, F.W., Cheng, H.L., Bunkenborg, J., Streeper, R.S., Mostoslavsky, R., Kim, J., Yancopoulos, G., Valenzuela, D., Murphy, A., Yang, Y., Chen, Y., Hirschey, M.D., Bronson, R.T., Haigis, M., Guarente, L.P., Farese, R.V., Jr., Weissman, S., Verdin, E., and Schwer, B., Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol, 2007. 27(24): p. 8807-14.

98. Verdin, E., AROuSing SIRT1: identification of a novel endogenous SIRT1 activator. Mol Cell, 2007. 28(3): p. 354-6.

97. Ahuja, N., Schwer, B., Carobbio, S., Waltregny, D., North, B.J., Castronovo, V., Maechler, P., and Verdin, E., Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J Biol Chem, 2007. 282(46): p. 33583-92.

96. Pagan, J.K., Arnold, J., Hanchard, K.J., Kumar, R., Bruno, T., Jones, M.J., Richard, D.J., Forrest, A., Spurdle, A., Verdin, E., Crossley, M., Fanciulli, M., Chenevix-Trench, G., Young, D.B., and Khanna, K.K., A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP. J Biol Chem, 2007. 282(20): p. 15248-57.

95. North, B.J. and Verdin, E., Mitotic regulation of SIRT2 by cyclin-dependent kinase 1- dependent phosphorylation. J Biol Chem, 2007. 282(27): p. 19546-55.

94. Saunders, L.R. and Verdin, E., Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene, 2007. 26(37): p. 5489-504.

93. North, B.J. and Verdin, E., Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One, 2007. 2(8): p. e784.

92. Ohnuma-Ishikawa, K., Morio, T., Yamada, T., Sugawara, Y., Ono, M., Nagasawa, M., Yasuda, A., Morimoto, C., Ohnuma, K., Dang, N.H., Hosoi, H., Verdin, E., and Mizutani, S., Knockdown of XAB2 enhances all-trans retinoic acid-induced cellular differentiation in all-trans retinoic acid-sensitive and -resistant cancer cells. Cancer Res, 2007. 67(3): p. 1019-29.

91. Parra, M., Mahmoudi, T., and Verdin, E., Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes. Genes Dev, 2007. 21(6): p. 638-43.

90. Parrella, G., Verdin, E., Gognalons, P., and Marchoux, G., Detection and characterization of tobacco mild green mosaic virus (TMGMV) large type isolate from trailing petunia in France. Commun Agric Appl Biol Sci, 2006. 71(3 Pt B): p. 1237-44.

89. Trapp, J., Jochum, A., Meier, R., Saunders, L., Marshall, B., Kunick, C., Verdin, E., Goekjian, P., Sippl, W., and Jung, M., Adenosine mimetics as inhibitors of NAD+- dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem, 2006. 49(25): p. 7307-16.

88. Mahmoudi, T., Parra, M., Vries, R.G., Kauder, S.E., Verrijzer, C.P., Ott, M., and Verdin, E., The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem, 2006. 281(29): p. 19960-8.

87. Williams, S.A., Chen, L.F., Kwon, H., Ruiz-Jarabo, C.M., Verdin, E., and Greene, W.C., NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J, 2006. 25(1): p. 139-49.

86. Saunders, L.R. and Verdin, E., Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. Mol Cancer Ther, 2006. 5(11): p. 2777-85.

85. Schwer, B., Bunkenborg, J., Verdin, R.O., Andersen, J.S., and Verdin, E., Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci U S A, 2006. 103(27): p. 10224-9.

84. Pagans, S., Pedal, A., North, B.J., Kaehlcke, K., Marshall, B.L., Dorr, A., Hetzer-Egger, C., Henklein, P., Frye, R., McBurney, M.W., Hruby, H., Jung, M., Verdin, E., and Ott, M., SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol, 2005. 3(2): p. e41. 

83. Olaharski, A.J., Rine, J., Marshall, B.L., Babiarz, J., Zhang, L., Verdin, E., and Smith, M.T., The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet, 2005. 1(6): p. e77.

82. Jayakumar, P., Berger, I., Autschbach, F., Weinstein, M., Funke, B., Verdin, E., Goldsmith, M.A., and Keppler, O.T., Tissue-resident macrophages are productively infected ex vivo by primary X4 isolates of human immunodeficiency virus type 1. J Virol, 2005. 79(8): p. 5220-6.

81. Lewinski, M.K., Bisgrove, D., Shinn, P., Chen, H., Hoffmann, C., Hannenhalli, S., Verdin, E., Berry, C.C., Ecker, J.R., and Bushman, F.D., Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol, 2005. 79(11): p. 6610-9.

80. North, B.J., Schwer, B., Ahuja, N., Marshall, B., and Verdin, E., Preparation of enzymatically active recombinant class III protein deacetylases. Methods, 2005. 36(4): p. 338-45.

79. Parra, M., Kasler, H., McKinsey, T.A., Olson, E.N., and Verdin, E., Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem, 2005. 280(14): p. 13762-70.

78. Waltregny, D., Glenisson, W., Tran, S.L., North, B.J., Verdin, E., Colige, A., and Castronovo, V., Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility.FASEB J, 2005. 19(8): p. 966-8.

77. Bisgrove, D., Lewinski, M., Bushman, F., and Verdin, E., Molecular mechanisms of HIV- 1 proviral latency. Expert Rev Anti Infect Ther, 2005. 3(5): p. 805-14.

76. Wittich, S., Scherf, H., Xie, C., Heltweg, B., Dequiedt, F., Verdin, E., Gerhauser, C., and Jung, M., Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines.Anticancer Drugs, 2005. 16(6): p. 635-43.

75. Heltweg, B., Dequiedt, F., Marshall, B.L., Brauch, C., Yoshida, M., Nishino, N., Verdin, E., and Jung, M., Subtype selective substrates for histone deacetylases. J Med Chem, 2004. 47(21): p. 5235-43.

74. Ott, M., Dorr, A., Hetzer-Egger, C., Kaehlcke, K., Schnolzer, M., Henklein, P., Cole, P., Zhou, M.M., and Verdin, E., Tat acetylation: a regulatory switch between early and late phases in HIV transcription elongation. Novartis Found Symp, 2004. 259: p. 182-93; discussion 193-6, 223-5.

73. Verdin, E., Dequiedt, F., and Kasler, H., HDAC7 regulates apoptosis in developing thymocytes. Novartis Found Symp, 2004. 259: p. 115-29; discussion 129-31, 163-9. 

72. Verdin, E., Dequiedt, F., Fischle, W., Frye, R., Marshall, B., and North, B., Measurement of mammalian histone deacetylase activity. Methods Enzymol, 2004. 377: p. 180-96.

71. Waltregny, D., De Leval, L., Glenisson, W., Ly Tran, S., North, B.J., Bellahcene, A., Weidle, U., Verdin, E., and Castronovo, V., Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol, 2004. 165(2): p. 553-64. 

70. North, B.J. and Verdin, E., Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol, 2004. 5(5): p. 224.

69. Waltregny, D., North, B., Van Mellaert, F., de Leval, J., Verdin, E., and Castronovo, V., Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem, 2004. 48(3): p. 273-90.

68. Williams, S.A., Chen, L.F., Kwon, H., Fenard, D., Bisgrove, D., Verdin, E., and Greene, W.C., Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem, 2004. 279(40): p. 42008-17.

67. Dequiedt, F., Kasler, H., Fischle, W., Kiermer, V., Weinstein, M., Herndier, B.G., and Verdin, E., HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity, 2003. 18(5): p. 687-98.

66. Kaehlcke, K., Dorr, A., Hetzer-Egger, C., Kiermer, V., Henklein, P., Schnoelzer, M., Loret, E., Cole, P.A., Verdin, E., and Ott, M., Acetylation of Tat defines a cyclinT1- independent step in HIV transactivation. Mol Cell, 2003. 12(1): p. 167-76.

65. Jordan, A., Bisgrove, D., and Verdin, E., HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 2003. 22(8): p. 1868-77.

64. North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M., and Verdin, E., The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell, 2003. 11(2): p. 437-44.

63. Verdin, E., Dequiedt, F., and Kasler, H.G., Class II histone deacetylases: versatile regulators. Trends Genet, 2003. 19(5): p. 286-93.

62. Heltweg, B., Dequiedt, F., Verdin, E., and Jung, M., Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. Anal Biochem, 2003. 319(1): p. 42-8.

61. Pion, M., Jordan, A., Biancotto, A., Dequiedt, F., Gondois-Rey, F., Rondeau, S., Vigne, R., Hejnar, J., Verdin, E., and Hirsch, I., Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol, 2003. 77(7): p. 4025-32.

60. Deroanne, C.F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.M., Nusgens, B.V., and Castronovo, V., Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 2002. 21(3): p. 427-36.

59. Dorr, A., Kiermer, V., Pedal, A., Rackwitz, H.R., Henklein, P., Schubert, U., Zhou, M.M., Verdin, E., and Ott, M., Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J, 2002. 21(11): p. 2715-23.

58. Fischle, W., Dequiedt, F., Hendzel, M.J., Guenther, M.G., Lazar, M.A., Voelter, W., and Verdin, E., Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell, 2002. 9(1): p. 45-57.

57. Borra, M.T., O'Neill, F.J., Jackson, M.D., Marshall, B., Verdin, E., Foltz, K.R., and Denu, J.M., Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases. J Biol Chem, 2002. 277(15): p. 12632-41.

56. Schwer, B., North, B.J., Frye, R.A., Ott, M., and Verdin, E., The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol, 2002. 158(4): p. 647-57. 

55. Murphy, J.C., Fischle, W., Verdin, E., and Sinclair, J.H., Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J, 2002. 21(5): p. 1112-20.

54. Mujtaba, S., He, Y., Zeng, L., Farooq, A., Carlson, J.E., Ott, M., Verdin, E., and Zhou, M.M., Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell, 2002. 9(3): p. 575-86.

53. Fischle, W., Dequiedt, F., Fillion, M., Hendzel, M.J., Voelter, W., and Verdin, E., Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem, 2001. 276(38): p. 35826-35.

52. Kruhlak, M.J., Hendzel, M.J., Fischle, W., Bertos, N.R., Hameed, S., Yang, X.J., Verdin, E., and Bazett-Jones, D.P., Regulation of global acetylation in mitosis through loss of histone acetyltransferases and deacetylases from chromatin. J Biol Chem, 2001. 276(41): p. 38307-19.

51. Jordan, A., Defechereux, P., and Verdin, E., The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J, 2001. 20(7): p. 1726-38.

50. Fischle, W., Kiermer, V., Dequiedt, F., and Verdin, E., The emerging role of class II histone deacetylases. Biochem Cell Biol, 2001. 79(3): p. 337-48.

49. Chen, L., Fischle, W., Verdin, E., and Greene, W.C., Duration of nuclear NF-kappaB  action regulated by reversible acetylation. Science, 2001. 293(5535): p. 1653-7.

48. Geenen, V. and Verdin, E., [Egg-cell complex, molecular embryology, human genome, then, human proteome].  Rev Med Liege, 2001. 56(3): p. 170.

47. Kruhlak, M.J., Lever, M.A., Fischle, W., Verdin, E., Bazett-Jones, D.P., and Hendzel,  M.J., Reduced mobility of the alternate splicing factor (ASF) through the nucleoplasm and steady state speckle compartments. J Cell Biol, 2000. 150(1): p. 41-51.

46. Huynh, K.D., Fischle, W., Verdin, E., and Bardwell, V.J., BCoR, a novel corepressor involved in BCL-6 repression.  Genes Dev, 2000. 14(14): p. 1810-23.

45. Verdin, E., Kobisch, M., Bove, J.M., Garnier, M., and Saillard, C., Use of an internal control in a nested-PCR assay for Mycoplasma hyopneumoniae detection and quantification in tracheobronchiolar washings from pigs. Mol Cell Probes, 2000. 14(6): p. 365-72.

44. Wang, J.K., Kiyokawa, E., Verdin, E., and Trono, D., The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A, 2000. 97(1): p. 394-9.

43. Guenther, M.G., Lane, W.S., Fischle, W., Verdin, E., Lazar, M.A., and Shiekhattar, R., A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev, 2000. 14(9): p. 1048-57.

42. Mahlknecht, U., Bucala, R., Hoelzer, D., and Verdin, E., High resolution physical mapping of human HDAC3, a potential tumor suppressor gene in the 5q31 region.  Cytogenet Cell Genet, 1999. 86(3-4): p. 237-9.

41. Fischle, W., Emiliani, S., Hendzel, M.J., Nagase, T., Nomura, N., Voelter, W., and Verdin, E., A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem, 1999. 274(17): p. 11713-2.

40. Mahlknecht, U., Bucala, R., and Verdin, E., Assignment of the histone deacetylase gene (Hdac3) to mouse chromosome 18B3 by in situ hybridization. Cytogenet Cell Genet, 1999. 84(3-4): p. 192-3.

39. Mahlknecht, U., Emiliani, S., Najfeld, V., Young, S., and Verdin, E., Genomic organization and chromosomal localization of the human histone deacetylase 3 gene. Genomics, 1999. 56(2): p. 197-202.

38. Mahlknecht, U., Hoelzer, D., Bucala, R., and Verdin, E., Cloning and characterization of the murine histone deacetylase (HDAC3). Biochem Biophys Res Commun, 1999. 263(2): p. 482-90.

37. Critchfield, J.W., Ho, O., Roberts, B.D., Van Lint, C., Verdin, E., and Butera, S.T., Isoquinolinesulphonamide derivatives inhibit transcriptional elongation of human immunodeficiency virus type 1 RNA in a promyelocytic model of latency. Antivir Chem Chemother, 1999. 10(5): p. 275-84.

36. Ott, M., Schnolzer, M., Garnica, J., Fischle, W., Emiliani, S., Rackwitz, H.R., and Verdin, E., Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol, 1999. 9(24): p. 1489-92.

35. Emiliani, S., Fischle, W., Van Lint, C., Al-Abed, Y., and Verdin, E., Characterization of a human RPD3 ortholog, HDAC3. Proc Natl Acad Sci U S A, 1998. 95(6): p. 2795-800.

34. Emiliani, S., Fischle, W., Ott, M., Van Lint, C., Amella, C.A., and Verdin, E., Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol, 1998. 72(2): p. 1666-70.

33. Kiermer, V., Van Lint, C., Briclet, D., Vanhulle, C., Kettmann, R., Verdin, E., Burny, A., and Droogmans, L., An interferon regulatory factor binding site in the U5 region of the bovine leukemia virus long terminal repeat stimulates Tax-independent gene expression. J Virol, 1998. 72(7): p. 5526-34.

32. Richon, V.M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R.A., and Marks, P.A., A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A, 1998. 95(6): p. 3003-7.

31. Herbein, G., Mahlknecht, U., Batliwalla, F., Gregersen, P., Pappas, T., Butler, J., O'Brien, W.A., and Verdin, E., Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature, 1998. 395(6698): p. 189-94.

30. Herbein, G., Van Lint, C., Lovett, J.L., and Verdin, E., Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes. J Virol, 1998. 72(1): p. 660-70.

29. Ott, M., Lovett, J.L., Mueller, L., and Verdin, E., Superinduction of IL-8 in T cells by HIV- 1 Tat protein is mediated through NF-kappaB factors. J Immunol, 1998. 160(6): p. 2872-80.

28. McCloskey, T.W., Ott, M., Tribble, E., Khan, S.A., Teichberg, S., Paul, M.O., Pahwa, S., Verdin, E., and Chirmule, N., Dual role of HIV Tat in regulation of apoptosis in T cells. J Immunol, 1997. 158(2): p. 1014-9.

27. Sheridan, P.L., Mayall, T.P., Verdin, E., and Jones, K.A., Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev, 1997. 11(24): p. 3327-40.

26. Ott, M., Emiliani, S., Van Lint, C., Herbein, G., Lovett, J., Chirmule, N., McCloskey, T., Pahwa, S., and Verdin, E., Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science, 1997. 275(5305): p. 1481-5

25. Van Lint, C., Amella, C.A., Emiliani, S., John, M., Jie, T., and Verdin, E., Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol, 1997. 71(8): p. 6113-27.

24. Emiliani, S., Van Lint, C., Fischle, W., Paras, P., Jr., Ott, M., Brady, J., and Verdin, E., A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A, 1996. 93(13): p. 6377-81.

23. Van Lint, C., Emiliani, S., and Verdin, E., The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr, 1996. 5(4-5): p. 245-53.

22. Van Lint, C., Emiliani, S., Ott, M., and Verdin, E., Transcriptional activation and  chromatin remodeling of the HIV-1 promoter in response to histone acetylation.  EMBO J, 1996. 15(5): p. 1112-20.

21. Verdin, E. and Van Lint, C., Internal transcriptional regulatory elements in HIV-1 and other retroviruses.  Cell Mol Biol (Noisy-le-grand), 1995. 41(3): p. 365-9.

20. el Kharroubi, A. and Verdin, E., Protein-DNA interactions within DNase I-hypersensitive sites located downstream of the HIV-1 promoter. J Biol Chem, 1994. 269(31): p. 19916-24.

19. Van Lint, C., Ghysdael, J., Paras, P., Jr., Burny, A., and Verdin, E., A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of human immunodeficiency virus type 1. J Virol, 1994. 68(4): p. 2632-48.

18. Verdin, E., Paras, P., Jr., and Van Lint, C., Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J, 1993. 12(8): p. 3249-59.

17. Sharpless, N.E., O'Brien, W.A., Verdin, E., Kufta, C.V., Chen, I.S., and Dubois-Dalcq, M., Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J Virol, 1992. 66(4): p. 2588-93.

16. Sharpless, N., Gilbert, D., Vandercam, B., Zhou, J.M., Verdin, E., Ronnett, G., Friedman, E., and Dubois-Dalcq, M., The restricted nature of HIV-1 tropism for cultured neural cells. Virology, 1992. 191(2): p. 813-25.

15. Montgomery, L.B., Kao, C.Y., Verdin, E., Cahill, C., and Maratos-Flier, E., Infection of a polarized epithelial cell line with wild-type reovirus leads to virus persistence and altered cellular function. J Gen Virol, 1991. 72 ( Pt 12): p. 2939-46.

14. Verdin, E., DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol, 1991. 65(12): p. 6790-9.

13. Van Lint, C., Burny, A., and Verdin, E., The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites. J Virol, 1991. 65(12): p. 7066-72.

12. Verdin, E., Becker, N., Bex, F., Droogmans, L., and Burny, A., Identification and characterization of an enhancer in the coding region of the genome of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A, 1990. 87(12): p. 4874-8. 

11. Verdin, E.M., King, G.L., and Maratos-Flier, E., Characterization of a common high- affinity receptor for reovirus serotypes 1 and 3 on endothelial cells. J Virol, 1989. 63(3): p. 1318-25.

10. Delchambre, M., Gheysen, D., Thines, D., Thiriart, C., Jacobs, E., Verdin, E., Horth, M., Burny, A., and Bex, F., The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J, 1989. 8(9): p. 2653-60.

9. Burny, A., Bex, F., Brasseur, R., Khim, M.C., Delchambre, M., Horth, M., and Verdin, E., Human immunodeficiency virus cell entry: new insights into the fusion mechanism. J Acquir Immune Defic Syndr, 1988. 1(6): p. 579-82.

8. Verdin, E.M., Lynn, S.P., Fields, B.N., and Maratos-Flier, E., Uptake of reovirus serotype 1 by the lungs from the bloodstream is mediated by the viral hemagglutinin. J Virol, 1988. 62(2): p. 545-51.

7. Maratos-Flier, E., Kao, C.Y., Verdin, E.M., and King, G.L., Receptor-mediated vectorial transcytosis of epidermal growth factor by Madin-Darby canine kidney cells. J Cell Biol, 1987. 105(4): p. 1595-601.

6. Verdin, E.M., Maratos-Flier, E., Kahn, C.R., Sodoyez, J.C., Sodoyez-Goffaux, F., De Vos, C.J., Lynn, S.P., and Fields, B.N., Visualization of viral clearance in the living animal. Science, 1987. 236(4800): p. 439-42.

5. Paolisso, G., Scheen, A.J., Verdin, E.M., Luyckx, A.S., and Lefebvre, P.J., Insulin oscillations per se do not affect glucose turnover parameters in normal man. J Clin Endocrinol Metab, 1986. 63(2): p. 520-5.

4. Verdin, E.M., Maratos-Flier, E., Carpentier, J.L., and Kahn, C.R., Persistent infection with a nontransforming RNA virus leads to impaired growth factor receptors and response. J Cell Physiol, 1986. 128(3): p. 457-65.

3. Verdin, E., Smitz, S., Thibaut, A., Born, J., Legros, J.J., and Luyckx, A., Adipsic hypernatremia in a patient with pseudotumor cerebri and the primary empty sella syndrome. J Endocrinol Invest, 1985. 8(4): p. 369-72.

2. Verdin, E.M. and Green, F.W., Jr., VIP and the pancreatic cholera syndrome. N Engl J Med, 1984. 310(22): p. 1465-6.

1. Castillo, M., Nemery, A., Verdin, E., Lefebvre, P.J., and Luyckx, A.S., Circadian profiles of blood glucose and plasma free insulin during treatment with semisynthetic and biosynthetic human insulin, and comparison with conventional monocomponent preparations. Eur J Clin Pharmacol, 1983. 25(6): p. 767-71.